ARS Pharmaceuticals Releases Q1 2026 Financial Results

AlphaStreet Newsdesk powered by AlphaStreet Intelligence

SPRY|EPS -$0.61 vs -$0.51 est (-19.6%)|Rev $22.7M|Net Loss $60.6M

ARS Pharmaceuticals, Inc. reported a wider-than-expected loss for Q1 2026 as the biopharmaceutical company continued investing heavily in commercializing its severe allergic reaction treatment. The company posted a diluted loss of $0.61 per share, missing the consensus estimate of $0.51 per share by 19.6%. The net loss totaled $60.6M for the quarter. Year-over-year, the per-share loss widened to $0.61 from $0.35 in Q1 2025, a 74.3% increase.

Revenue provided a brighter spot, totaling $22.7M for the quarter, up 184.7% from the $8.0M recorded in Q1 2025. The company’s flagship neffy product generated $17.5M in product revenue during the period. Healthcare providers prescribing neffy reached 28,000 for the quarter, reflecting the company’s expanding commercial reach in the severe allergic reaction treatment market.

ARS Pharmaceuticals added 10,000 schools to its neffyinSchools program at quarter end, demonstrating continued penetration into the educational sector where severe allergic reactions represent a critical safety concern. Wall Street consensus stands at 6 buy, 1 hold, 0 sell, suggesting analyst confidence in the company’s commercial trajectory despite the widening loss as it scales operations.

A detailed analysis of ARS Pharmaceuticals, Inc.’s quarter follows shortly on AlphaStreet.

This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.